It would be worthwhile to further evaluate hRNase5/ANG as a predictive biomarker for EGFR inhibitor therapy in pancreatic cancer in a systematic way through prospective clinical trials in the future. The gene discussed is EGFR; the disease is familial pancreatic carcinoma.